BiVictriX Strengthens Board and Completes Fund-raising Round
Updated: Aug 19, 2019
Alderley Park, United Kingdom — BiVictriX announces today that Dr Mike Carter has joined its board as a Non-executive Director, and that it has completed an internal fund-raising round enabling development of its project portfolio and technology platform.
Dr Mike Carter brings more than 40 years of board and senior management experience in the life sciences sector, including an active role in the development of more than 20 medicines. He served as a member of the ICI Pharmaceuticals board from 1986 to 1998, in addition to senior management roles in both international clinical development and international marketing. In 1998 he became the first venture partner at SV Healthcare Partners, an appointment that he continues to hold, and is also on the strategic advisory committee of Healthcare Royalty Partners. He also holds non-executive director positions on the boards of Artios, Karus, GTX Inc., Oxagen/Atopix and Kesios.
BiVictriX has successfully completed an internal fundraising round, in which all major shareholders participated. These included the existing institutional shareholders, Alderley Park Ventures and Development Bank Wales, as well as existing and new High Net Worth individuals. The funding will allow the Company to complete non-clinical studies in preclinical models of leukaemia on its lead projecy BVX100, develop its Bi-Cygni technology platform, and initiate additional projects ahead of a planned Series A round later in the year.
“I am delighted to welcome Mike to the board of BiVictriX. His deep understanding and experience of the Life Sciences sector, both in the development and commercialization of cancer therapeutics, and in building successful biotechnology companies, will be invaluable as BiVictriX continues to progress its project portfolio. I look forward to his contributions in supporting the company in its next phases of development.” says Norman Molyneux, Chairman of board of directors at BiVictriX.
“I’m very pleased and excited to be joining the BiVictrix board at this critical moment in the company’s development. BiVictrix’s capability to discover and develop a new generation of targeted cancer immunotherapeutics has the potential to change the way that cancer is treated, and I look forward to working with the company’s management as we advance these drugs towards the clinic”, says Dr Mike Carter.
The funding round was advised by Acceleris Capital Limited.
For further information, please contact Tiffany Thorn, CEO, BiVictriX Ltd., phone: +44 7908 719566
BiVictriX Ltd. Is a privately-held biopharmaceutical company based in the UK that employs its proprietary Bi-Cygni® technology platform to discover and develop the next generations of targeted immunotherapeutics for the treatment of cancer. The Bi-Cygni® platform enables the identification of pairs of surface antigens for obligate bispecific therapeutics, enhancing the specificity for the tumour, andreducing the treatment-related toxicity that currently hinders the development of otherwise promising cancer therapeutics. BiVictriX links Bi-Cygni® to expertise in the design, discovery and development of antibody drug conjugates (ADCs), and its current lead project, BVX001, is a bispecific ADC for the treatment of Acute Myeloid Leukemia (AML).